NorthWest Biotherapeutics Inc (NWBO): FEMike said: Phase I reviews the tech...

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Wednesday, 02/28/2024 9:23:02 PM

Wednesday, February 28, 2024 9:23:02 PM

FEMike said:

Phase I reviews the technical validity of the application.

Phase II reviews the scientific aspect of the application.

Show me the link that proves what you say above is true, and that you are not making it up.

Keep Last Read

Replies (2) Next 10 Prev Next

Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM

InvestorsHub NewsWire

FEATURED Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • Jun 14, 2024 2:07 AM

Only $200 per official company press release!